DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
WSJ’s Daniela Hernandez - 1 Elizabeth Smelov - 1 Eli Lilly ’ - 1 Ozempic - 1 Jaclyn Bjorklund - 1 Eli Lilly - 1 ’ Ozempic - 1 Mounjaro - 1
Top related locs:
Elizabeth Smelov U.S Novo Louisiana
Top related orgs:
Novo Nordisk - 2 CNN - 1 US Food and Drug Administration - 1

Search resuls for: "Eli Lilly’s Mounjaro"


3 mentions found


☆ Eli Lilly’s Mounjaro Approved for Weight Loss in the U.S.
  + stars: | 2023-11-08 | by ( Peter Loftus | ) www.wsj.com   time to read: 1 min
Earlier: Some drugs initially approved to treat Type 2 diabetes are now being used for cosmetic weight loss. WSJ’s Daniela Hernandez explains how they work, their side effects, and concerns over unintended consequences. Illustration: Elizabeth SmelovU.S. drug regulators have approved expanding the use of Eli Lilly ’s diabetes drug Mounjaro to include the treatment of obesity. The Food and Drug Administration’s decision Wednesday furthers the rapid rise of Mounjaro—and similar-acting therapies Ozempic and Wegovy from Novo Nordisk —that have in a matter of months reshaped the treatment of obesity and doctors’ understanding of its roots.
Persons: WSJ’s Daniela Hernandez, Elizabeth Smelov, Eli Lilly ’, Ozempic Organizations: Novo Nordisk Locations: Elizabeth Smelov U.S, Novo
☆ Woman sues drug makers of Ozempic and Mounjaro over severe gastrointestinal issues
  + stars: | 2023-08-03 | by ( Jamiel Lynch Jamie Gumbrecht | Jamiel Lynch | Jamie Gumbrecht | ) edition.cnn.com   time to read: +5 min
CNN —In a lawsuit filed on Wednesday, a Louisiana woman is claiming she has suffered severe injuries due to her use of Ozempic and Mounjaro, which were prescribed by her doctor. Attorneys for Jaclyn Bjorklund claim that the 44-year-old woman used Ozempic for more than a year until around July 2023 and then began using Mounjaro. She is suing the makers of both drugs, Novo Nordisk and Eli Lilly, for failing to warn of the risk of severe gastrointestinal events that could be caused by taking the medications. “As a result of using Defendants’ Ozempic and Mounjaro, Plaintiff was caused to suffer from severe gastrointestinal events, and as a result sustained severe and permanent personal injuries, pain, suffering, and emotional distress, and incurred medical expenses,” the lawsuit alleges. CNN has reached out to both Novo Nordisk and Eli Lilly for comment on the lawsuit.
Persons: Jaclyn Bjorklund, Eli Lilly, ’ Ozempic, Mounjaro, Plaintiff, Bjorklund, “, Novo’s, Eli Lilly’s Mounjaro Organizations: CNN, Novo Nordisk, US Food and Drug Administration Locations: Louisiana
☆ Big Pharma will muscle in on obesity gold rush
  + stars: | 2022-11-28 | by ( Aimee Donnellan | ) www.reuters.com   time to read: +4 min
LONDON, Nov 28 (Reuters Breakingviews) - Obesity drugs are a modern day gold rush for drugmakers. By then, the obesity market could total $50 billion, according to Morgan Stanley. But a plausible 50% price cut would lower annual sales to $25 billion. Reuters GraphicsFollow @aimeedonnellan on TwitterCONTEXT NEWSSales of Novo Nordisk’s obesity drugs Wegovy and Saxenda reached nearly $1.2 billion in 2021, up 50% versus the previous year. Morgan Stanley analysts expect the obesity market to grow to $50 billion in annual sales by 2030.
0 next >>
Total: 3